CLINUVEL Expands Singapore RD&I Centre for Next-Generation Peptide Therapies
CLINUVEL Pharmaceuticals Limited (ASX: CUV) has announced a major expansion of its VALLAURIX Research, Development & Innovation Centre in Singapore, reinforcing its long-term strategy to advance peptide-based medicines. Supported by the Singapore Economic Development Board, the five-year investment aims to transform the facility into a global hub for developing long-acting, controlled-release drug formulations. The upgraded centre will integrate advanced formulation and analytical capabilities while ensuring ongoing programs continue without disruption.
CLINUVEL plans to gradually increase specialist staff as part of its commitment to innovation and vertical integration within peptide therapeutics. This expansion strengthens the company’s position in delivering next-generation treatments targeting genetic, metabolic and acute disorders, leveraging Singapore’s strong biotech ecosystem. By enhancing its ability to design and commercialise advanced delivery platforms, CLINUVEL aims to accelerate the translation of its melanocortin research into impactful therapies for patients worldwide.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
CLINUVEL Expands Singapore RD&I Centre for Next-Generation Peptide Therapies
CLINUVEL Pharmaceuticals Limited (ASX: CUV) has announced a major expansion of its VALLAURIX Research, Development & Innovation Centre in Singapore, reinforcing its long-term strategy to advance peptide-based medicines. Supported by the Singapore Economic Development Board, the five-year investment aims to transform the facility into a global hub for developing long-acting, controlled-release drug formulations. The upgraded centre will integrate advanced formulation and analytical capabilities while ensuring ongoing programs continue without disruption.
CLINUVEL plans to gradually increase specialist staff as part of its commitment to innovation and vertical integration within peptide therapeutics. This expansion strengthens the company’s position in delivering next-generation treatments targeting genetic, metabolic and acute disorders, leveraging Singapore’s strong biotech ecosystem. By enhancing its ability to design and commercialise advanced delivery platforms, CLINUVEL aims to accelerate the translation of its melanocortin research into impactful therapies for patients worldwide.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au